PDCD1 and non-small cell lung carcinoma: Although ICIs have been evaluated in NSCLC [8,9,10,11], with efficacy benefits over leading chemotherapeutics (e.g., docetaxel), adaptive resistance to PD-1/PD-L1 blockade has been documented [9].